Cedric Ghellamallah

Cedric Ghellamallah is a notable inventor based in France. He has made significant contributions to the field of pharmaceutical compounds, particularly in the development of innovative treatments for various mental health and neurological disorders. His work focuses on compounds that interact with trace amine-associated receptors (TAARs), which play a crucial role in the treatment of several conditions.

Latest Patents

Although Cedric Ghellamallah currently holds no patents, his latest inventions include Triazole Carboxamide Derivatives and Pyrazole Derivatives. The Triazole Carboxamide Derivatives are designed to treat a range of disorders, including depression, anxiety disorders, bipolar disorder, ADHD, and various neurological diseases such as Parkinson's and Alzheimer's. These compounds exhibit a good affinity for TAARs, particularly TAAR1, making them promising candidates for therapeutic applications. Similarly, the Pyrazole Derivatives also target TAARs and are intended for the treatment of similar conditions.

Career Highlights

Cedric Ghellamallah is associated with F. Hoffmann-La Roche AG, a leading global healthcare company. His work at Roche has allowed him to focus on the development of innovative pharmaceutical solutions that address critical health issues. His research is aimed at improving the quality of life for individuals suffering from complex disorders.

Collaborations

Cedric collaborates with various professionals in the field, including his coworker Roger Norcross. Their combined expertise contributes to the advancement of research and development in pharmaceutical innovations.

Conclusion

Cedric Ghellamallah is a dedicated inventor whose work in pharmaceutical compounds holds promise for the treatment of various mental health and neurological disorders. His innovative approach and collaboration with industry professionals position him as a key figure in the ongoing quest for effective therapies.